Perpetual Ltd Has $2.10 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Perpetual Ltd boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 117.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 8,931 shares of the biopharmaceutical company’s stock after purchasing an additional 4,819 shares during the period. Perpetual Ltd’s holdings in Alnylam Pharmaceuticals were worth $2,102,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ALNY. Huntington National Bank boosted its position in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares in the last quarter. Hollencrest Capital Management bought a new stake in Alnylam Pharmaceuticals during the third quarter worth $29,000. Washington Trust Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $42,000. True Wealth Design LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $45,000. 92.97% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on ALNY. Piper Sandler reaffirmed an “overweight” rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Sanford C. Bernstein reduced their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Cantor Fitzgerald reiterated a “neutral” rating and set a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Scotiabank increased their price objective on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Finally, Canaccord Genuity Group boosted their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $298.61.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the sale, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now owns 13,191 shares in the company, valued at $3,310,677.18. This represents a 10.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,122 shares of company stock worth $2,540,455 in the last quarter. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $264.99 on Wednesday. The company has a market cap of $34.18 billion, a P/E ratio of -101.14 and a beta of 0.34. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The business has a 50-day moving average price of $245.87 and a two-hundred day moving average price of $259.94. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. The business’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.15 EPS. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.18 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.